ABSTRACT
The use of underwater sensor networks (UWSNs) offers great advantages in many automatic observation services such as water monitoring (ocean, sea, etc.) and registering of geological events (landslides, earthquakes). However, UWSNs have many more limitations than terrestrial sensor networks (smaller bandwidth, higher delays, etc.) with new requirements such as low power consumption by nodes or being able to select appropriate routes in a dynamic topology due to water currents and movements. To cope with these problems, the use of a routing protocol is very important. In this paper we propose a routing technique that adapts to changes in the network topology, avoiding multiple retransmissions that would affect its overall performance. This protocol is energy-efficient and is implemented using a fuzzy analytical hierarchical process (FAHP) under multi-criteria decision making (MCDM) to make an intelligent routing decision based on objectives, criteria and alternatives. To select the next node on the route, several comparison matrices are used: number of hops, distances to the sink node, and number of neighbors. The results show that the proposed setup behaves similarly to other existing underwater sensor network routing schemes using fuzzy schemes such as SPRINT.
ABSTRACT
METHODS: We conducted a single-center, medical records review study of all patients with RA, PsA, and SpA on GLM treatment attending a large rheumatology department from 2010 to 2017. Times from start to end of GLM treatment were collected, as well as sociodemographic, clinical, and safety variables. Golimumab retention rate was estimated by the Kaplan-Meier method, and comparison across diseases was analyzed with the Mantel-Haenszel statistic (log-rank test). Cox proportional hazards regression models were used to identify factors associated with GLM discontinuation. RESULTS: In the study period, a total of 212 patients (61 RA, 48 PsA, 103 SpA) were prescribed GLM. Retention rates were 72% in the first year, 61% in the second, 56% in the third, and 38% at 5 years. Differences were statistically significant across diseases (median times to GLM discontinuation were 50.2, 46.0, and 38.7 months for RA, SpA, and PsA, respectively) and according to the number of previous biologic therapies (55.2 months in biologic-naive patients vs 14.0 months in patients with ≥2 previous biologics; p < 0.001). The use of concomitant conventional synthetic disease-modifying antirheumatic drugs was associated with a lower probability of discontinuation (hazards ratio [HR], 0.57; 95% confidence interval [CI], 0.33-0.97). Female sex (HR, 1.84; 95% CI, 1.07-3.17) and having used 2 biologics before GLM (HR, 2.99; 95% CI, 1.76-5.06) were associated with increased discontinuation rates. Twenty-three patients (10.9%) had at least 1 serious adverse event. CONCLUSIONS: In a real-life setting, GLM shows appropriate long-term safety-effectiveness ratio.
Subject(s)
Antibodies, Monoclonal , Antirheumatic Agents , Arthritis, Psoriatic , Arthritis, Rheumatoid , Medication Adherence/statistics & numerical data , Spondylarthritis , Adult , Aged , Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Psoriatic/drug therapy , Arthritis, Rheumatoid/drug therapy , Female , Humans , Male , Middle Aged , Spain , Spondylarthritis/drug therapy , Treatment OutcomeABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Osteoarthropathy, Secondary Hypertrophic/complications , Osteoarthropathy, Secondary Hypertrophic/diagnosis , Osteoarthropathy, Secondary Hypertrophic/therapy , Arthralgia/diagnosis , Arthralgia/drug therapy , Chemoembolization, Therapeutic/instrumentation , Chemoembolization, Therapeutic/methods , Osteoarthropathy, Secondary Hypertrophic/physiopathology , Osteoarthropathy, Secondary Hypertrophic , Polymyalgia Rheumatica/complications , Polymyalgia Rheumatica , Arthralgia/etiology , Arthralgia , Periostitis , Chemoembolization, Therapeutic/standards , Chemoembolization, Therapeutic/trends , Chemoembolization, TherapeuticABSTRACT
La agenesia del tercer molar es una de las controversias mas suscitadas dentro de la odontología actual y sus especialidades. Por lo tanto, el desarrollo filogenético de la cavidad oral se debe tener en cuenta. Este estudio de tipo descriptivo, es una contribución a la aclaración de este interrogante. Se llevó a cabo una revisión de 1304 radiografías panorámicas de pacientes tratados en ortodoncia y cirugía, y se elaboró con el fin de determinar la mayor prevalencia de agenesia en una población de adolescentes entre 11 y 16 años en Santafé de Bogotá, Colombia, encontrando que la agenesia del tercer molar puede ocurrir indiscriminadamente en cualquiera de los molares, siendo mas frecuente la agenesia total que la parcial
